IMMUNEONCO-B repurchases 133,600 H shares, reducing free float by 0.03%

Bulletin Express

Jun 25

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that on 25 June 2026 it repurchased 133,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.44 to HKD 3.64, for a total consideration of HKD 0.47 million. The volume-weighted average repurchase price was HKD 3.55 per share.

Following the transaction, issued shares (excluding treasury shares) decreased to 419.13 million, representing a 0.03 % reduction from the 419.26 million shares outstanding on 24 June 2026. Treasury share holdings rose to 1.35 million, while the company’s total issued share capital remained unchanged at 420.48 million shares.

The buyback forms part of the mandate approved on 28 May 2026, which authorises the company to repurchase up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 1.35 million shares, equivalent to 0.31 % of the issued share base as of the mandate date.

Under Hong Kong listing rules, IMMUNEONCO-B is subject to a 30-day moratorium on new share issues or treasury-share disposals, ending 25 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155853589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155853589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155853589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155853589","market":"hk","top_or_hot":-1,"title":"IMMUNEONCO-B repurchases 133,600 H shares, reducing free float by 0.03%","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that on 25 June 2026 it repurchased 133,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.44 to HKD 3.64, for a total consideration of HKD 0.47 million. The volume-weighted average repurchase price was HKD 3.55 per share.</p>\n<p>Following the transaction, issued shares (excluding treasury shares) decreased to 419.13 million, representing a 0.03 % reduction from the 419.26 million shares outstanding on 24 June 2026. Treasury share holdings rose to 1.35 million, while the company’s total issued share capital remained unchanged at 420.48 million shares.</p>\n<p>The buyback forms part of the mandate approved on 28 May 2026, which authorises the company to repurchase up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 1.35 million shares, equivalent to 0.31 % of the issued share base as of the mandate date.</p>\n<p>Under Hong Kong listing rules, IMMUNEONCO-B is subject to a 30-day moratorium on new share issues or treasury-share disposals, ending 25 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B repurchases 133,600 H shares, reducing free float by 0.03%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B repurchases 133,600 H shares, reducing free float by 0.03%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-25 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that on 25 June 2026 it repurchased 133,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.44 to HKD 3.64, for a total consideration of HKD 0.47 million. The volume-weighted average repurchase price was HKD 3.55 per share.</p>\n<p>Following the transaction, issued shares (excluding treasury shares) decreased to 419.13 million, representing a 0.03 % reduction from the 419.26 million shares outstanding on 24 June 2026. Treasury share holdings rose to 1.35 million, while the company’s total issued share capital remained unchanged at 420.48 million shares.</p>\n<p>The buyback forms part of the mandate approved on 28 May 2026, which authorises the company to repurchase up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 1.35 million shares, equivalent to 0.31 % of the issued share base as of the mandate date.</p>\n<p>Under Hong Kong listing rules, IMMUNEONCO-B is subject to a 30-day moratorium on new share issues or treasury-share disposals, ending 25 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1155853589","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155853589","pubTimestamp":1782392820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that on 25 June 2026 it repurchased 133,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.44 to HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B回购13.36万股H股，自由流通量减少0.03%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that on 25 June 2026 it repurchased 133,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.44 to HKD 3.64, for a total consideration of HKD 0.47 million. The volume-weighted average repurchase price was HKD 3.55 per share.\nFollowing the transaction, issued shares (excluding treasury shares) decreased to 419.13 million, representing a 0.03 % reduction from the 419.26 million shares outstanding on 24 June 2026. Treasury share holdings rose to 1.35 million, while the company’s total issued share capital remained unchanged at 420.48 million shares.\nThe buyback forms part of the mandate approved on 28 May 2026, which authorises the company to repurchase up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 1.35 million shares, equivalent to 0.31 % of the issued share base as of the mandate date.\nUnder Hong Kong listing rules, IMMUNEONCO-B is subject to a 30-day moratorium on new share issues or treasury-share disposals, ending 25 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}